Enfermedades Infecciosas
Buscador de publicaciones
Sólo se han incluido artículos originales, editoriales y revisiones.
-
García-Lledó A, Gómez-Pavón J, González Del Castillo J, Hernández-Sampelayo T, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, Bouza E.
Pharmacological treatment of COVID-19: an opinion paper.
REVISTA ESPANOLA DE QUIMIOTERAPIA . 35(2): 115-130. Nº de citas: 30
-
Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A.
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
Life Science Alliance . 5(4): . Nº de citas: 8
-
Martínez-Sanz J, Ron R, Moreno E, Sánchez-Conde M, Muriel A, López Cortés LF, Blanco JR, Pineda JA, Mena Á, Calzado Isbert S, Moreno S, Serrano-Villar S.
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
Frontiers in immunology . 13: 873408-873408. Nº de citas: 2
-
Albasanz-Puig A, Durà-Miralles X, Laporte-Amargós J, Mussetti A, Ruiz-Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M, Montejo JM, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Morales HMP, Brunel AS, García E, Isler B, Kern WV, Retamar-Gentil P, Aguado JM, Montero M, Kanj SS, Sipahi OR, Calik S, Márquez-Gómez I, Marin JI, Gomes MZR, Hemmati P, Araos R, Peghin M, Del Pozo JL, Yáñez L, Tilley R, Manzur A, Novo A, Pallarès N, Bergas A, Carratalà J, Gudiol C, On Behalf Of The Ironic Study Group.
Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia.
Microorganisms . 10(4): .
-
Moreno S, Alcázar B, Dueñas C, González Del Castillo J, Olalla J, Antela A.
Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.
DRUG DESIGN DEVELOPMENT AND THERAPY . 16: 827-841. Nº de citas: 5
-
Maza MDC, Úbeda M, Delgado P, Horndler L, Llamas MA, van Santen HM, Alarcón B, Abia D, García-Bermejo L, Serrano-Villar S, Bastolla U, Fresno M.
ACE2 Serum Levels as Predictor of Infectability and Outcome in COVID-19.
Frontiers in immunology . 13: 836516-836516. Nº de citas: 5
-
Serrano-Villar S, López-Huertas MR, Jiménez D, Galera C, Martínez-Sanz J, Moreno E, Muriel A, Gutiérrez F, Busca C, Portilla J, Bisbal O, Iribarren JA, Tejerina F, de Los Santos I, Moreno S.
Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens.
Frontiers in immunology . 13: 848630-848630. Nº de citas: 3
-
Manzano M, Talavera-Rodríguez A, Moreno E, Madrid N, Gosalbes MJ, Ron R, Dronda F, Pérez-Molina JA, Lanza VF, Díaz J, Moreno S, Navia B, Serrano-Villar S.
Relationship of Diet to Gut Microbiota and Inflammatory Biomarkers in People with HIV.
Nutrients . 14(6): . Nº de citas: 1
-
Albóniga OE, Jiménez D, Sánchez-Conde M, Vizcarra P, Ron R, Herrera S, Martínez-Sanz J, Moreno E, Moreno S, Barbas C, Serrano-Villar S.
Metabolic Snapshot of Plasma Samples Reveals New Pathways Implicated in SARS-CoV-2 Pathogenesis.
JOURNAL OF PROTEOME RESEARCH . 21(3): 623-634. Nº de citas: 1
-
Sainz T, Diaz L, Rojo D, Clemente MI, Barbas C, Gosalbes MJ, Jimenez-Hernandez N, Escosa L, Guillen S, Ramos JT, Muñoz-Fernández MÁ, Navarro ML, Mellado MJ, Serrano-Villar S.
Targeting the Gut Microbiota of Vertically HIV-Infected Children to Decrease Inflammation and Immunoactivation: A Pilot Clinical Trial
Nutrients . 14(5): . Nº de citas: 6
-
Podzamczer D, Micán R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masiá M, Gómez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro Á, Bernal E, Vinuesa D, Knobel H, Troya J, Macías J, Montero M, Sanz J, Navarro-Alcaraz A, Caicedo A, Fernández G, Martínez E, Moreno S.
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
Open forum infectious diseases . 9(3): .
-
Balandín B, Ballesteros D, Pintado V, Soriano-Cuesta C, Cid-Tovar I, Sancho-González M, Pérez-Pedrero MJ, Chicot M, Asensio-Martín MJ, Silva JA, de Luna RR, Gesso CM, Rodríguez-Serrano DA, Martínez-Sagasti F, Royuela A.
Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS . 59(3): 106536-106536. Nº de citas: 10
-
Sherrill-Mix S, Yang M, Aldrovandi GM, Brenchley JM, Bushman FD, Collman RG, Dandekar S, Klatt NR, Lagenaur LA, Landay AL, Paredes R, Tachedjian G, Turpin JA, Serrano-Villar S, Lozupone CA, Ghosh M.
A Summary of the Sixth International Workshop on Microbiome in HIV Pathogenesis, Prevention, and Treatment
AIDS RESEARCH AND HUMAN RETROVIRUSES . 38(3): 173-180.
-
Fursa O, Mocroft A, Lazarus JV, Amele S, Lundgren J, Matulionyte R, Rasmussen LD, Rockstroh JK, Parczewski M, Jilich D, Moreno S, Vassilenko A, Lacombe K, Wandeler G, Borodulina E, Brännström J, Wiese L, Orkin C, Behrens GMN, Mansinho K, Portu JJ, Peters L, EuroSIDA study.
The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences
AIDS . 36(3): 423-435. Nº de citas: 9
-
Vallejo A, Martín-Hondarza A, Gómez S, Velasco H, Vizcarra P, Haemmerle J, Casado JL.
Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity
FRONTIERS IN MICROBIOLOGY . 12: 812729-812729. Nº de citas: 5
-
Ruiz-Galiana, Julian, de Lucas Ramos, Pilar, Garcia-Botella, Alejandra, Garcia-Lledo, Alberto, Gomez-Pavon, Javier, Gonzalez del Castillo, Juan, Hernandez-Sampelayo, Teresa, Cruz Martin-Delgado, Mari, Martin Sanchez, Francisco Javier, Martinez-Selles, Manuel, Molero Garcia, Jose Maria, Moreno Guillen, Santiago, Rodriguez-Artalejo, Fernando, Canton, Rafael, Bouza, Emilio.
Persistence and viability of SARS-CoV-2 in primary infection and reinfections
REVISTA ESPANOLA DE QUIMIOTERAPIA . 35(1): 1-6. Nº de citas: 3
-
de Lucas Ramos, Pilar, Garcia-Botella, Alejandra, Garcia-Lledo, Alberto, Gomez-Pavon, Javier, Gonzalez del Castillo, Juan, Hernandez-Sampelayo, Teresa, Cruz Martin-Delgado, Mari, Martin Sanchez, Francisco Javier, Martinez-Selles, Manuel, Molero Garcia, Jose Maria, Moreno Guillen, Santiago, Rodriguez-Artalejo, Fernando, Ruiz-Galiana, Julian, Canton, Rafael, Bouza, Emilio.
Actions and attitudes on the immunized patients against SARS-CoV-2
REVISTA ESPANOLA DE QUIMIOTERAPIA . 35(1): 7-15. Nº de citas: 1
-
Del Amo J, Polo R, Moreno S, Jarrín I, Hernán MA.
SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment
AIDS . 36(2): 161-168. Nº de citas: 17